RESUMO
Effects of paraben toxicity, i.e., endocrine-disruption properties, are in the focus of researchers for decades, but still - they are a hot subject of debate. Parabens are aliphatic esters of p-hydroxybenzoic acid, which are widely used as antimicrobial agents for the preservation of cosmetics, pharmaceuticals and foods. Mostly used parabens are methyl-, ethyl-, propyl- and butylparaben. Although the toxicity of parabens is reported in animals and in in vitro studies, it cannot be taken for granted when discussing hazards for human health due to an unrealistic exposure -safety profile. Many studies have demonstrated that parabens are non-teratogenic, non-mutagenic, non-carcinogenic and the real evidence for their toxicity in humans has not been established. For now, methyl-, ethyl- and propylparaben are considered safe for use in cosmetics and pharmaceuticals within the recommended range of doses. Regarding alternatives for parabens, a variety of approaches have been proposed, but every substitute would need to be tested rigorously for toxicity and safety.
Assuntos
Disruptores Endócrinos/toxicidade , Parabenos/toxicidade , Animais , Cosméticos , Disruptores Endócrinos/efeitos adversos , Disruptores Endócrinos/farmacocinética , Humanos , Parabenos/efeitos adversos , Parabenos/química , Parabenos/farmacocinéticaRESUMO
This study was aimed at determining if oxidative stress imbalance in testes of rats occurs after n-butylparaben (n-ButP) exposure. Young male Sprague-Dawley rats were subcutaneously treated with n-ButP during one spermatogenic cycle (57 days) at 0 (control-oil), 150, 300 and 600â¯mg/kg/d with peanut oil as vehicle. A non-vehicle control group was also included. Antioxidant enzyme activities (superoxide dismutase, catalase, glutathione reductase, and glutathione peroxidase) and levels of reduced and oxidized glutathione were measured in testes. Lipid peroxidation and H2O2 concentrations were also assessed. Results showed an increase of oxidative stress in oil-treated groups, excepting 600â¯mg/kg/d, suggesting oxidative stress due to peanut oil. A possible antioxidant effect due to n-ButP and its metabolites was suggested at 600â¯mg/kg/d, the only group not showing oxidative stress. An increase of calcium concentration in testes was also observed. On the other hand, a physiologically-based pharmacokinetic (PBPK) model was developed and the concentrations of n-ButP and its metabolites were simulated in plasma and testes. The peak concentration (Cmax) in testes was found slightly higher than that in plasma. The current results indicate that peanut oil can cause oxidative stress while high doses of n-ButP can act as antioxidant agent in testes.
Assuntos
Disruptores Endócrinos/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Parabenos/toxicidade , Testículo/efeitos dos fármacos , Animais , Antioxidantes/farmacocinética , Antioxidantes/toxicidade , Arachis/química , Biomarcadores/metabolismo , Cálcio/metabolismo , Catalase/metabolismo , Disruptores Endócrinos/farmacocinética , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Glutationa Redutase/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Parabenos/farmacocinética , Óleo de Amendoim/toxicidade , Ratos Sprague-DawleyRESUMO
BACKGROUND: The harmful effects of endocrine disrupting compounds (EDCs) on human health are generally well-known, and exposure during fetal development may have lasting effects. Fetal exposure to bisphenol A (BPA) has been recently relatively well-studied; however, less is known about alternatives such as bisphenol S (BPS), bisphenol F (BPF) and bisphenol AF (BPAF), which have started to appear in consumer products. Parabens are another widespread group of EDCs, with confirmed transplacental passage. The usage of many cosmetic, pharmaceutical and consumer products during the pregnancy that may contain parabens and bisphenols has led to the need for investigation. OBJECTIVES: To shed more light into the transplacental transport of BPA, its alternatives, and parabens, and to study their relation to fetal steroidogenesis. METHODS: BPA, BPS, BPF, BPAF, methylparaben, ethylparaben, propylparaben, butylparaben, benzylparaben and 15 steroids including estrogens, corticoids, androgens and immunomodulatory ones were determined in 27 maternal (37th week of pregnancy) and cord plasma samples using liquid chromatography - tandem mass spectrometry methods. RESULTS: In cord blood, significantly higher BPA levels (p=0.0455) were observed compared to maternal plasma. The results from multiple regression models showed that in cord blood, methylparaben (ß=-0.027, p=0.027), propylparaben (ß=-0.025, p=0.03) and the sum of all measured parabens (ß=-0.037, p=0.015) were inversely associated with testosterone levels. CONCLUSION: To the best of our knowledge, this is the first study reporting the simultaneous detection of BPA, alternative bisphenols, parabens and steroids in maternal and cord plasma. Our study confirmed the transplacental transport of BPA, with likely accumulation in the fetal compartment. The negative association of cord blood parabens and testosterone levels points to possible risks with respect to importance of testosterone for prenatal male development.
Assuntos
Disruptores Endócrinos , Sangue Fetal , Parabenos , Adulto , Compostos Benzidrílicos/farmacocinética , Compostos Benzidrílicos/farmacologia , Cromatografia Líquida , Disruptores Endócrinos/farmacocinética , Estrogênios/fisiologia , Feminino , Sangue Fetal/química , Humanos , Recém-Nascido , Masculino , Exposição Materna , Parabenos/farmacocinética , Fenóis/farmacocinética , GravidezRESUMO
The diffusion process through a non-porous barrier membrane depends on the properties of the drug, vehicle and membrane. The aim of the current study was to investigate whether a series of oily vehicles might have the potential to interact to varying degrees with synthetic membranes and to determine whether any such interaction might affect the permeation of co-formulated permeants: methylparaben (MP); butylparaben (BP) or caffeine (CF). The oils (isopropyl myristate (IPM), isohexadecane (IHD), hexadecane (HD), oleic acid (OA) and liquid paraffin (LP)) and membranes (silicone, high density polyethylene and polyurethane) employed in the study were selected such that they displayed a range of different structural, and physicochemical properties. Diffusion studies showed that many of the vehicles were not inert and did interact with the membranes resulting in a modification of the permeants' flux when corrected for membrane thickness (e.g. normalized flux of MP increased from 1.25±0.13µgcm(-1)h(-1) in LP to 17.94±0.25µgcm(-1)h(-1)in IPM). The oils were sorbed differently to membranes (range of weight gain: 2.2±0.2% for polyurethane with LP to 105.6±1.1% for silicone with IHD). Membrane interaction was apparently dependent upon the physicochemical properties including; size, shape, flexibility and the Hansen solubility parameter values of both the membranes and oils. Sorbed oils resulted in modified permeant diffusion through the membranes. No simple correlation was found to exist between the Hansen solubility parameters of the oils or swelling of the membrane and the normalized fluxes of the three compounds investigated. More sophisticated modelling would appear to be required to delineate and quantify the key molecular parameters of membrane, permeant and vehicle compatibility and their interactions of relevance to membrane permeation.
Assuntos
Cafeína/administração & dosagem , Excipientes/química , Parabenos/administração & dosagem , Cafeína/química , Cafeína/farmacocinética , Química Farmacêutica/métodos , Difusão , Membranas Artificiais , Óleos/química , Parabenos/química , Parabenos/farmacocinética , Absorção Cutânea , SolubilidadeRESUMO
A highly sensitive gas chromatography-mass spectrometry (GC-MS) method for the determination of endocrine disrupting chemicals (EDCs) including parabens, alkylphenols, phenylphenols, bisphenol A and triclosan in human breast milk, blood and urine samples is proposed. Blood and milk require a pretreatment to remove proteins and other substances potentially interfering with the continuous solid-phase extraction (SPE) system used; on the other hand, urine samples can be directly introduced into the system after filtering. Analytes are retained on a LiChrolut EN column and derivatized by silylation following elution with acetonitrile. The resulting trimethylsilyl derivatives are determined by GC-MS. The proposed method exhibited good linearity (r(2)>0.995) for all target EDCs over the concentration range 0.7-10,000ng/l in urine, and 3.3-50,000ng/l in blood and milk. Also, it provided low limits of detection (0.2-1.8ng/l in urine, and 1.0-9.0ng/l in blood and milk), good precision (relative standard deviations less than 7%) and recoveries from 86 to 104%. A total of 24 human fluid samples were analyzed and most found to contain some target EDC at concentrations from 0.10 to 14µg/l.
Assuntos
Compostos Benzidrílicos , Disruptores Endócrinos , Leite Humano/química , Parabenos/análise , Fenóis , Triclosan , Compostos Benzidrílicos/sangue , Compostos Benzidrílicos/urina , Disruptores Endócrinos/sangue , Disruptores Endócrinos/urina , Cromatografia Gasosa-Espectrometria de Massas/instrumentação , Cromatografia Gasosa-Espectrometria de Massas/métodos , Voluntários Saudáveis , Humanos , Técnicas In Vitro , Limite de Detecção , Parabenos/farmacocinética , Fenóis/sangue , Fenóis/urina , Padrões de Referência , Reprodutibilidade dos Testes , Extração em Fase Sólida/instrumentação , Extração em Fase Sólida/métodos , Triclosan/sangue , Triclosan/urinaRESUMO
Parabens have been reported as potential endocrine disrupters and are widely used in consumer projects including cosmetics, foods and pharmaceuticals. We report on the development of a PBPK model for methyl-, propyl-, and butylparaben. The model was parameterized through a combination of QSAR for tissue solubility and quantitative in vitro to in vivo extrapolation (IVIVE) for hydrolysis in portals of entry including intestine and skin as well as in the primary site of metabolism, the liver. Overall, the model provided very good agreement with published time-course data in blood and urine from controlled dosing studies in rat and human, and demonstrates the potential value of quantitative IVIVE in expanding the use of human biomonitoring data in safety assessment. An in vitro based cumulative margin of safety (MOS) was calculated by comparing the effective concentrations from an in vitro assay of estrogenicity to the free paraben concentrations predicted by the model to be associated with the 95th percentile urine concentrations reported in NHANES (2009-2010 collection period). The calculated MOS for adult females was 108, whereas the MOS for males was 444.
Assuntos
Disruptores Endócrinos/farmacocinética , Disruptores Endócrinos/toxicidade , Poluentes Ambientais/farmacocinética , Modelos Biológicos , Parabenos/farmacocinética , Parabenos/toxicidade , Testes de Toxicidade/métodos , Adulto , Animais , Biotransformação , Células Cultivadas , Disruptores Endócrinos/sangue , Disruptores Endócrinos/química , Poluentes Ambientais/sangue , Poluentes Ambientais/química , Poluentes Ambientais/toxicidade , Feminino , Genes Reporter , Humanos , Hidrólise , Modelos Lineares , Masculino , Inquéritos Nutricionais , Parabenos/química , Ratos Sprague-Dawley , Ratos Wistar , Receptores de Estrogênio/efeitos dos fármacos , Receptores de Estrogênio/genética , Receptores de Estrogênio/metabolismo , Medição de Risco , Fatores de Risco , Solubilidade , Distribuição TecidualRESUMO
A framework for understanding the complexity of cancer development was established by Hanahan and Weinberg in their definition of the hallmarks of cancer. In this review, we consider the evidence that parabens can enable development in human breast epithelial cells of four of six of the basic hallmarks, one of two of the emerging hallmarks and one of two of the enabling characteristics. In Hallmark 1, parabens have been measured as present in 99% of human breast tissue samples, possess oestrogenic activity and can stimulate sustained proliferation of human breast cancer cells at concentrations measurable in the breast. In Hallmark 2, parabens can inhibit the suppression of breast cancer cell growth by hydroxytamoxifen, and through binding to the oestrogen-related receptor gamma may prevent its deactivation by growth inhibitors. In Hallmark 3, in the 10 nm-1 µm range, parabens give a dose-dependent evasion of apoptosis in high-risk donor breast epithelial cells. In Hallmark 4, long-term exposure (>20 weeks) to parabens leads to increased migratory and invasive activity in human breast cancer cells, properties that are linked to the metastatic process. As an emerging hallmark methylparaben has been shown in human breast epithelial cells to increase mTOR, a key regulator of energy metabolism. As an enabling characteristic parabens can cause DNA damage at high concentrations in the short term but more work is needed to investigate long-term, low-dose mixtures. The ability of parabens to enable multiple cancer hallmarks in human breast epithelial cells provides grounds for regulatory review of the implications of the presence of parabens in human breast tissue.
Assuntos
Neoplasias da Mama/patologia , Células Epiteliais/efeitos dos fármacos , Parabenos/toxicidade , Apoptose , Disponibilidade Biológica , Mama/citologia , Mama/efeitos dos fármacos , Mama/patologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Dano ao DNA , Exposição Ambiental , Feminino , Instabilidade Genômica , Humanos , Parabenos/farmacocinética , Receptores de Estrogênio/metabolismo , Serina-Treonina Quinases TOR/genética , Serina-Treonina Quinases TOR/metabolismo , Tamoxifeno/análogos & derivados , Tamoxifeno/farmacologiaRESUMO
Parabens are among the most frequently used preservatives to inhibit microbial growth and extend the shelf life of a range of consumer products. The objective of the present study was to gain insight into the metabolism of parabens in breast cancer cells (MCF7) since they have demonstrated estrogenic activity towards these cells and have been detected in breast cancer tissues. The toxicity of parabens to MCF7 cells was determined using MTT assays. Hydrolysis of methyl-, butyl and benzyl-paraben to p-hydroxybenzoic acid was analyzed in cultured MCF7 cells and in cellular homogenates. Glucuronidation and sulfoconjugation were studied in MCF7 homogenates, and parabens were analyzed by HPLC. Methyl-paraben was shown to be far less toxic than butyl and benzyl-paraben. Parabens were completely stable in MCF7 homogenates whereas p-nitrophenyl acetate, a substrate type, underwent hydrolysis. MCF7 cell homogenates did not express glucuronidation and sulfoconjugation activities toward parabens. The higher stability of parabens may explain their accumulation in breast cancer tissue as previously reported in the literature.
Assuntos
Neoplasias da Mama/metabolismo , Conservantes de Alimentos/metabolismo , Parabenos/metabolismo , Parabenos/toxicidade , Linhagem Celular Tumoral , Cromatografia Líquida de Alta Pressão , Feminino , Conservantes de Alimentos/farmacocinética , Conservantes de Alimentos/toxicidade , Glucuronosiltransferase/metabolismo , Humanos , Hidrólise , Parabenos/farmacocinética , Sulfotransferases/metabolismoRESUMO
Although, it is well-established that information on the metabolism of a substance is important in the evaluation of its toxic potential, there is limited experience with incorporating metabolic aspects into in vitro tests for endocrine disrupters. The aim of the current study was a) to study different in vitro systems for biotransformation of ten known endocrine disrupting chemicals (EDs): five azole fungicides, three parabens and 2 phthalates, b) to determine possible changes in the ability of the EDs to bind and activate the thyroid receptor (TR) in the in vitro T-screen assay after biotransformation and c) to investigate the endogenous metabolic capacity of the GH3 cells, the cell line used in the T-screen assay, which is a proliferation assay used for the in vitro detection of agonistic and antagonistic properties of compounds at the level of the TR. The two in vitro metabolizing systems tested the human liver S9 mix and the PCB-induced rat microsomes gave an almost complete metabolic transformation of the tested parabens and phthalates. No marked difference the effects in the T-screen assay was observed between the parent compounds and the effects of the tested metabolic extracts. The GH3 cells themselves significantly metabolized the two tested phthalates dimethyl phthalate (DMP) and diethyl phthalate (DEP). Overall the results and qualitative data from the current study show that an in vitro metabolizing system using liver S9 or microsomes could be a convenient method for the incorporation of metabolic and toxicokinetic aspects into in vitro testing for endocrine disrupting effects.
Assuntos
Antifúngicos/farmacocinética , Disruptores Endócrinos/farmacocinética , Fungicidas Industriais/farmacocinética , Receptores dos Hormônios Tireóideos/metabolismo , Animais , Azóis/farmacocinética , Bioensaio , Biotransformação , Linhagem Celular , Linhagem Celular Tumoral , Humanos , Técnicas In Vitro , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Parabenos/farmacocinética , Ácidos Ftálicos/farmacocinética , RatosRESUMO
Parabens are preservatives used in a wide range of cosmetic products, including products for children, and some are permitted in foods. However, there is concern for endocrine disrupting effects. This paper critically discusses the conclusions of recent reviews and original research papers and provides an overview of studies on toxicokinetics. After dermal uptake, parabens are hydrolyzed and conjugated and excreted in urine. Despite high total dermal uptake of paraben and metabolites, little intact paraben can be recovered in blood and urine. Paraben metabolites may play a role in the endocrine disruption seen in experimental animals and studies are needed to determine human levels of parabens and metabolites. Overall, the estrogenic burden of parabens and their metabolites in blood may exceed the action of endogenous estradiol in childhood and the safety margin for propylparaben is very low when comparing worst-case exposure to NOAELs from experimental studies in rats and mice.
Assuntos
Disruptores Endócrinos/toxicidade , Exposição Ambiental/efeitos adversos , Poluentes Ambientais/toxicidade , Parabenos/toxicidade , Conservantes Farmacêuticos/toxicidade , Administração Cutânea , Animais , Disruptores Endócrinos/classificação , Disruptores Endócrinos/farmacocinética , Poluentes Ambientais/classificação , Poluentes Ambientais/farmacocinética , Estradiol/fisiologia , Humanos , Camundongos , Nível de Efeito Adverso não Observado , Parabenos/classificação , Parabenos/farmacocinética , Conservantes Farmacêuticos/classificação , Conservantes Farmacêuticos/farmacocinética , Ratos , Medição de RiscoRESUMO
This toxicology update reviews research over the past four years since publication in 2004 of the first measurement of intact esters of p-hydroxybenzoic acid (parabens) in human breast cancer tissues, and the suggestion that their presence in the human body might originate from topical application of bodycare cosmetics. The presence of intact paraben esters in human body tissues has now been confirmed by independent measurements in human urine, and the ability of parabens to penetrate human skin intact without breakdown by esterases and to be absorbed systemically has been demonstrated through studies not only in vitro but also in vivo using healthy human subjects. Using a wide variety of assay systems in vitro and in vivo, the oestrogen agonist properties of parabens together with their common metabolite (p-hydroxybenzoic acid) have been extensively documented, and, in addition, the parabens have now also been shown to possess androgen antagonist activity, to act as inhibitors of sulfotransferase enzymes and to possess genotoxic activity. With the continued use of parabens in the majority of bodycare cosmetics, there is a need to carry out detailed evaluation of the potential for parabens, together with other oestrogenic and genotoxic co-formulants of bodycare cosmetics, to increase female breast cancer incidence, to interfere with male reproductive functions and to influence development of malignant melanoma which has also recently been shown to be influenced by oestrogenic stimulation.
Assuntos
Disruptores Endócrinos/toxicidade , Doenças do Sistema Endócrino/induzido quimicamente , Exposição Ambiental/efeitos adversos , Exposição Ambiental/estatística & dados numéricos , Esterases/metabolismo , Parabenos/toxicidade , Antagonistas de Androgênios/toxicidade , Animais , Doenças do Sistema Endócrino/epidemiologia , Ésteres/toxicidade , Estrogênios não Esteroides/toxicidade , Humanos , Absorção Intestinal , Legislação de Medicamentos , Mutagênicos/toxicidade , Parabenos/análise , Parabenos/farmacocinética , Receptores de Estrogênio/efeitos dos fármacos , Medição de Risco , Neoplasias Cutâneas/induzido quimicamente , Neoplasias Cutâneas/epidemiologiaAssuntos
Cosméticos/farmacocinética , Parabenos/farmacocinética , Pele/metabolismo , Neoplasias da Mama/etiologia , Cosméticos/efeitos adversos , Proteínas de Ligação a DNA , Derme/metabolismo , Epiderme/metabolismo , Feminino , Proteínas de Homeodomínio/efeitos dos fármacos , Humanos , Técnicas In Vitro , Masculino , Proteínas Nucleares/efeitos dos fármacos , Parabenos/efeitos adversos , Permeabilidade , Proteínas de Ligação a RNA , Absorção CutâneaRESUMO
The metabolism and toxicity of ethyl 4-hydroxybenzoate (4-HEB) were investigated in vitro using tyrosinase enzyme, a melanoma molecular target, and CYP2E1 induced rat liver microsomes, and in human SK-MEL-28 melanoma cells. The results were compared to 4-hydroxyanisole (4-HA). At 90 min, 4-HEB was metabolized 48% by tyrosinase and 26% by liver microsomes while the extent of 4-HA metabolism was 196% and 88%, respectively. The IC50 (day 2) of 4-HEB and 4-HA towards SK-MEL-28 cells were 75 and 50 microM, respectively. Dicoumarol, a diaphorase inhibitor, and 1-bromoheptane, a GSH depleting agent, increased 4-HEB toxicity towards SK-MEL-28 cells indicating o-quinone formation played an important role in 4-HEB induced cell toxicity. Addition of ascorbic acid and GSH to the media was effective in preventing 4-HEB cell toxicity. Cyclosporin A and trifluoperazine, inhibitors of permeability transition pore in mitochondria, were significantly potent in inhibiting 4-HEB cell toxicity. 4-HEB caused time-dependent decline in intracellular GSH concentration which preceded cell death. 4-HEB also led to reactive oxygen species (ROS) formation in melanoma cells which exacerbated by dicoumarol and 1-bromoheptane whereas cyclosporin A and trifluoperazine prevented it. Our findings suggest that the mechanisms of 4-HEB toxicity in SK-MEL-28 were o-quinone formation, intracellular GSH depletion, ROS formation and mitochondrial toxicity.
Assuntos
Melanoma/metabolismo , Parabenos/farmacocinética , Animais , Biotransformação , Linhagem Celular Tumoral , Glutationa/metabolismo , Humanos , Masculino , Monofenol Mono-Oxigenase/fisiologia , Parabenos/toxicidade , Ratos , Ratos Sprague-Dawley , Espécies Reativas de Oxigênio , SolubilidadeRESUMO
Concern is continuously raised about the safety of parabens which are present in most of the cosmetic preparations. In this investigation, methyl-, ethyl-, propyl- and butyl paraben (MP, EP, PP, BP), in a commercial cosmetic lotion, were deposited on human skin fragments, collected after surgical operations. Permeated parabens were determined after their passage through human epidermis-dermis layers, fixed on Franz diffusion cells. Bovine serum albumin (3%) was employed as receptor fluid. Then, parabens were assessed by liquid chromatography. The objective of this research was to determine the permeation of these molecules through human epidermis-dermis layers, and their possible passage to body tissues and/or accumulation in skin layers. Two groups of experiments were performed. In the first experimental group (G1), unique doses of the cosmetic were deposited on skin fragments fixed on Franz cells (n = 6), at time 0 h, followed with different withdrawn times of the receptor fluid at 12, 24 and 36 h. G1 results demonstrated that parabens penetration was influenced by their lipophilicity: more lipophilic the parabens were (BP > PP > EP > MP), less they crossed the skin layers (BP < PP < EP < MP). The second experimental group (G2) was constituted of three equal deposits on each Franz cell (n = 6) at different hour times 0, 12 and 24 h followed with three withdrawn times of the receptor fluid at 12, 24 and 36 h. The G2 results indicated that investigated parabens had significant increasing permeations in skin layers. This situation provokes the accumulation of these molecules which were considered by some authors as the cause of skin toxicities and carcinogenicity.
Assuntos
Cosméticos/farmacocinética , Parabenos/farmacocinética , Absorção Cutânea , Pele/metabolismo , Adulto , Cosméticos/metabolismo , Derme/metabolismo , Epiderme/metabolismo , Feminino , Humanos , Técnicas In Vitro , Parabenos/metabolismo , Permeabilidade , Fatores de TempoRESUMO
Parabens (p-hydroxybenzoate esters) are a group of widely used preservatives in topically applied cosmetic and pharmaceutical products. Parabens display weak associations with the estrogen receptors in vitro or in cell based models, but do exhibit estrogenic effects in animal models. It is our hypothesis that parabens exert their estrogenic effects, in part, by elevating levels of estrogens through inhibition of estrogen sulfotransferases (SULTs) in skin. We report here the results of a structure-activity-relationship of parabens as inhibitors of estrogen sulfation in human skin cytosolic fractions and normal human epidermal keratinocytes. Similar to reports of paraben estrogenicity and estrogen receptor affinity, the potency of SULT inhibition increased as the paraben ester chain length increased. Butylparaben was found to be the most potent of the parabens in skin cytosol, yielding an IC(50) value of 37+/-5 microM. Butylparaben blocked the skin cytosol sulfation of estradiol and estrone, but not the androgen dehydroepiandrosterone. The parabens were also tested as inhibitors of SULT activity in a cellular system, with normal human epidermal keratinocytes. The potency of butylparaben increased three-fold in these cells relative to the IC(50) value from skin cytosol. Overall, these results suggest chronic topical application of parabens may lead to prolonged estrogenic effects in skin as a result of inhibition of estrogen sulfotransferase activity. Accordingly, the skin anti-aging benefits of many topical cosmetics and pharmaceuticals could be derived, in part, from the estrogenicity of parabens.
Assuntos
Parabenos/farmacologia , Conservantes Farmacêuticos/farmacologia , Pele/efeitos dos fármacos , Pele/enzimologia , Sulfotransferases/antagonistas & inibidores , Cromatografia Líquida , Citosol/metabolismo , Estradiol/metabolismo , Antagonistas de Estrogênios/farmacocinética , Antagonistas de Estrogênios/farmacologia , Estrogênios/farmacocinética , Estrogênios/farmacologia , Feminino , Humanos , Concentração Inibidora 50 , Queratinócitos/efeitos dos fármacos , Queratinócitos/enzimologia , Fígado/efeitos dos fármacos , Fígado/metabolismo , Parabenos/farmacocinética , Conservantes Farmacêuticos/farmacocinética , Pele/citologia , Relação Estrutura-Atividade , Especificidade por Substrato , Sulfotransferases/metabolismo , Enxofre/metabolismo , Espectrometria de Massas em TandemRESUMO
Parabens are a group of the alkyl esters of p-hydroxybenzoic acid and typically include methylparaben, ethylparaben, propylparaben, butylparaben, isobutylparaben, isopropylparaben, and benzylparaben. Parabens (or their salts) are widely used as preservatives in cosmetics, toiletries, and pharmaceuticals due to their relatively low toxicity profile and a long history of safe use. Testing of parabens has revealed to varying degrees that individual paraben compounds have weakly estrogenic activity in some in vitro screening tests, such as ligand binding to the estrogen receptor, regulation of CAT gene expression, and proliferation of MCF-7 cells. Reported in vivo effects include increased uterine weight (i.e., butyl-, isobutyl-, and benzylparaben) and male reproductive-tract effects (i.e., butyl- and propylparaben). However, in relation to estrogen as a control during in vivo studies, the parabens with activity are many orders of magnitude less active than estrogen. While exposure to sufficient doses of exogenous estrogen can increase the risk of certain adverse effects, the presumption that similar risks might also result from exposure to endocrine-active chemicals (EACs) with far weaker activity is still speculative. In assessing the likelihood that exposure to weakly active EACs might be etiologically associated with adverse effects due to an endocrine-mediated mode of action, it is paramount to consider both the doses and the potency of such compounds in comparison with estrogen. In this review, a comparative approach involving both dose and potency is used to assess whether in utero or adult exposure to parabens might be associated with adverse effects mediated via an estrogen-modulating mode of action. In utilizing this approach, the paraben doses required to produce estrogenic effects in vivo are compared with the doses of either 17beta-estradiol or diethylstilbestrol (DES) that are well established in their ability to affect endocrine activity. Where possible and appropriate, emphasis is placed on direct comparisons with human data with either 17beta-estradiol or DES, since this does not require extrapolation from animal data with the uncertainties inherent in such comparisons. Based on these comparisons using worst-case assumptions pertaining to total daily exposures to parabens and dose/potency comparisons with both human and animal no-observed-effect levels (NOELs) and lowest-observed-effect levels (LOELs) for estrogen or DES, it is biologically implausible that parabens could increase the risk of any estrogen-mediated endpoint, including effects on the male reproductive tract or breast cancer. Additional analysis based on the concept of a hygiene-based margin of safety (HBMOS), a comparative approach for assessing the estrogen activities of weakly active EACs, demonstrates that worst-case daily exposure to parabens would present substantially less risk relative to exposure to naturally occurring EACs in the diet such as the phytoestrogen daidzein.
Assuntos
Sistema Endócrino/efeitos dos fármacos , Moduladores de Receptor Estrogênico/efeitos adversos , Parabenos/efeitos adversos , Conservantes Farmacêuticos/efeitos adversos , Animais , Moduladores de Receptor Estrogênico/farmacocinética , Moduladores de Receptor Estrogênico/toxicidade , Feminino , Humanos , Masculino , Nível de Efeito Adverso não Observado , Parabenos/farmacocinética , Parabenos/toxicidade , Conservantes Farmacêuticos/farmacocinética , Conservantes Farmacêuticos/toxicidade , RiscoRESUMO
Parabens are widely used as preservatives in food, cosmetic and pharmaceutical products. Acute, subchronic, and chronic studies in rodents indicate that parabens are practically non-toxic. Parabens are rapidly absorbed, metabolized, and excreted. In individuals with normal skin, parabens are, for the most part, non-irritating and non-sensitizing. However, application of compounds containing parabens to damaged or broken skin has resulted in sensitization. Genotoxicity testing of parabens in a variety of in vitro and in vivo studies primarily gave negative results. The paraben structure is not indicative of carcinogenic potential, and experimental studies support these observations. Some animal studies have reported adverse reproductive effects of parabens. In an uterotrophic assay, methyl and butyl paraben administered orally to immature rats were inactive, while subcutaneous administration of butyl paraben produced a weak positive response. The ability of parabens to transactivate the estrogen receptor in vitro increases with alkyl group size. The detection of parabens in a small number of breast tumor tissue samples and adverse reproductive effects of parabens in animals has provoked controversy over the continued use of these substances. However, the possible estrogenic hazard of parabens on the basis of the available studies is equivocal, and fails to consider the metabolism and elimination rates of parabens, which are dose, route, and species dependent. In light of the recent controversy over the estrogenic potential of parabens, conduct of a reproductive toxicity study may be warranted.
Assuntos
Conservantes de Alimentos/toxicidade , Parabenos/toxicidade , Animais , Cosméticos , Excipientes , Conservantes de Alimentos/efeitos adversos , Humanos , Parabenos/efeitos adversos , Parabenos/farmacocinéticaRESUMO
Methyl paraben (CAS No. 99-76-3) is a methyl ester of p-hydroxybenzoic acid. It is a stable, non-volatile compound used as an antimicrobial preservative in foods, drugs and cosmetics for over 50 years. Methyl paraben is readily and completely absorbed through the skin and from the gastrointestinal tract. It is hydrolyzed to p-hydroxybenzoic acid, conjugated, and the conjugates are rapidly excreted in the urine. There is no evidence of accumulation. Acute toxicity studies in animals indicate that methyl paraben is practically non-toxic by both oral and parenteral routes. In a population with normal skin, methyl paraben is practically non-irritating and non-sensitizing. In chronic administration studies, no-observed-effect levels (NOEL) as high as 1050 mg/kg have been reported and a no-observed-adverse-effect level (NOAEL) in the rat of 5700 mg/kg is posited. Methyl paraben is not carcinogenic or mutagenic. It is not teratogenic or embryotoxic and is negative in the uterotrophic assay. The mechanism of cytotoxic action of parabens may be linked to mitochondrial failure dependent on induction of membrane permeability transition accompanied by the mitochondrial depolarization and depletion of cellular ATP through uncoupling of oxidative phosphorylation. Parabens are reported to cause contact dermatitis reactions in some individuals on cutaneous exposure. Parabens have been implicated in numerous cases of contact sensitivity associated with cutaneous exposure; however, the mechanism of this sensitivity is unknown. Sensitization has occurred when medications containing parabens have been applied to damaged or broken skin. Allergic reactions to ingested parabens have been reported, although rigorous evidence of the allergenicity of ingested paraben is lacking.
Assuntos
Parabenos/efeitos adversos , Animais , Bactérias/efeitos dos fármacos , Testes de Carcinogenicidade , Cosméticos , Aditivos Alimentares , Humanos , Imunidade/efeitos dos fármacos , Testes de Mutagenicidade , Nível de Efeito Adverso não Observado , Parabenos/farmacocinética , Parabenos/toxicidade , Dermatopatias/induzido quimicamente , Tecnologia FarmacêuticaRESUMO
Propyl paraben (CAS no. 94-13-3) is a stable, non-volatile compound used as an antimicrobial preservative in foods, drugs and cosmetics for over 50 years. It is an ester of p-hydroxybenzoate. Propyl paraben is readily absorbed via the gastrointestinal tract and dermis. It is hydrolyzed to p-hydroxybenzoic acid, conjugated and the conjugates are rapidly excreted in the urine. There is no evidence of accumulation. Acute toxicity studies in animals indicate that propyl paraben is relatively non-toxic by both oral and parenteral routes, although it is mildly irritating to the skin. Following chronic administration, no-observed-effect levels (NOEL) as high as 1200-4000 mg/kg have been reported and a no-observed-adverse-effect level (NOAEL) in the rat of 5500 mg/kg is posited. Propyl paraben is not carcinogenic, mutagenic or clastogenic. It is not cytogenic in vitro in the absence of carboxyesterase inhibitors. The mechanism of propyl paraben may be linked to mitochondrial failure dependent on induction of membrane permeability transition accompanied by the mitochondrial depolarization and depletion of cellular ATP through uncoupling of oxidative phosphorylation. Sensitization has occurred when medications containing parabens have been applied to damaged or broken skin. Parabens have been implicated in numerous cases of contact sensitivity associated with cutaneous exposure, but high concentrations of 5-15% in patch testing are needed to elicit reaction in susceptible individuals. Allergic reactions to ingested parabens have been reported, although rigorous evidence of the allergenicity of ingested paraben is lacking.
Assuntos
Dermatite Alérgica de Contato/etiologia , Conservantes de Alimentos/efeitos adversos , Parabenos/efeitos adversos , Animais , Cosméticos , Conservantes de Alimentos/farmacocinética , Conservantes de Alimentos/toxicidade , Humanos , Modelos Animais , Nível de Efeito Adverso não Observado , Parabenos/farmacocinética , Parabenos/toxicidade , Testes do Emplastro , Conservantes Farmacêuticos/efeitos adversos , Conservantes Farmacêuticos/farmacocinética , Conservantes Farmacêuticos/toxicidade , SegurançaRESUMO
Analogs of the aromatic constituent of calichemicins were labeled with 131I by exchange reactions. Radiochemical yield for methyl-4-hydroxy-5-iodo-2,3-dimethoxy-6-methylbenzoate was approx. 90%. For methyl-4-benzyloxy-2-hydroxy-3-iodo-6-methylbenzoate the yield was about 30%. Biodistribution studies were carried out in mice following intravenous administration of tracer doses. Average brain uptake of the first compound at 3 min was 0.28%, and that of the second 1.96%. Tissue distribution of the two compounds elsewhere was similar in nature. High uptake was observed initially in the liver; this reduced with time, while radioactivity in the GI-tract increased. The benzylated compound appeared potentially useful for designing a brain imaging radiopharmaceutical.